Reaction

Acute Febrile Neutrophilic Dermatosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,283 reports · 65 co-occurring drugs

As of the last recalculation, Acute Febrile Neutrophilic Dermatosis appears in 2,283 FAERS reports alongside 65 co-occurring drug terms. The strongest observed disproportionality signal is AZACITIDINE (PRR 29.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Azacitidine	93	29.7	29.8
Azacitidine For	50	25.6	25.7
Daspone	22	20.8	20.8
Dapsone Gel, 5%	22	20.8	20.8
Dapsone	22	19.0	19.0
Micafungin Sodium	15	16.2	16.3
Tretinoin	14	15.8	15.8
Azathioprine	141	15.5	15.5
Filgrastim	55	13.6	13.7
Anakinra	23	12.8	12.8
Colchicine	36	12.6	12.7
Minocycline	16	12.6	12.6
Cefazolin Sodium	15	11.4	11.4
Amikacin	21	11.3	11.3
Adalimumab-Aaty	53	10.4	10.4
Trimethoprim	13	10.1	10.1
Cefazolin	10	10.0	10.0
Hydroxyurea	23	10.0	10.0
Cefepime Hydrochloride	17	9.7	9.7
Cytarabine	62	9.6	9.7
Ceftriaxone	34	9.6	9.6
Bendamustine Hcl	16	9.5	9.5
Adalimumab-Fkjp	47	9.4	9.4
Nitrofurantoin	16	8.9	8.9
Nitrofurantoin (Monohydrate/Macrocrystals)	16	8.8	8.8
Ceftriaxone Sodium	36	8.7	8.7
Adalimumab-Adaz	49	8.6	8.6
Erlotinib	9	8.5	8.5
Bendamustine Hydrochloride	11	8.4	8.4
Piperacillin Sodium,Tazobactam Sodium	23	8.0	8.0
Piperacillin And Tazobactam	11	7.9	7.9
Sulfamethoxazole And Trimethoprim	70	7.8	7.8
Cefepime	12	7.7	7.7
Ado-Trastuzumab Emtansine	7	7.6	7.6
Piperacillin Sodium And Tazobactam Sodium	16	7.5	7.5
Valganciclovir Hydrochloride Powder,	9	6.7	6.8
Cladribine	7	6.7	6.7
Erlotinib Hydrochloride	9	6.6	6.6
Mesalamine	38	6.3	6.3
Linezolid	19	5.9	5.9
Posaconazole Delayed-Release	7	5.8	5.8
Tizanidine	15	5.8	5.8
Valacyclovir	26	5.7	5.7
Voriconazole Injection	13	5.5	5.5
Meropenem	19	5.4	5.4
Sirolimus	8	5.4	5.4
Ixazomib	16	5.1	5.1
Venetoclax	34	5.1	5.1
Trametinib	13	4.9	4.9
Vemurafenib	6	4.6	4.6
Docetaxel Anhydrous	33	4.5	4.5
Docetaxel	33	4.5	4.5
Posaconazole	8	4.5	4.5
Ipilimumab	21	4.5	4.5
Dabrafenib	10	4.3	4.3
Bortezomib	40	4.1	4.1
Ifosfamide	9	3.8	3.8
Deferasirox	11	3.8	3.8
Carboplatin	51	3.7	3.7
Encorafenib	4	3.7	3.7
Pegfilgrastim	37	3.5	3.5
Golimumab	29	3.1	3.1
Gefitinib	3	3.0	3.0
Dasatinib	12	3.0	3.0
Isotretinoin	14	2.6	2.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.